Nuclear magnetic resonance diagnostic agent, and method for detecting or diagnosing state of cell, tissue or organ in subject using same

Patent metadata

Field	Value
Publication number	US-11633505-B2
Application number	US-201314650530-A
Country	US
Kind code	B2
Filing date	Dec 9, 2013
Priority date	Dec 11, 2012
Publication date	Apr 25, 2023
Grant date	Apr 25, 2023

Abstract

[Problem]
To provide a nuclear magnetic resonance diagnostic agent that has a lower toxicity to organisms and reduced side effects and yet has a site specificity toward a specific cell, tissue, organ, etc.
[Solution]
When ALA or an ALA derivative is administered in vivo, a metabolite thereof is accumulated in a specific cell, tissue, organ, etc. Focusing on this phenomenon, a nuclear magnetic resonance analysis was performed on a site wherein the metabolite of ALA that had been administered in vivo would be possibly accumulated. As a result, it was surprisingly found that ALA and an ALA derivative are useful as a diagnostic agent whereby the aforesaid problem can be solved.

First claim

What is claimed is:

1. A method for diagnosing glioblastoma in a subject, comprising:
(1) a step of administering an MRI contrast agent comprising 5-aminolevulinic acid or a salt thereof orally to a living human or non-human animal subject,
(2) a step of applying MRI to the living human or non-human animal subject, utilizing nuclear magnetic resonance, wherein the MRI employs the Rapid Acquisition with Relaxation Enhancement (RARE) method;
(3) a step of obtaining a T2-weighted image of accumulated protoporphyrin IX with respect to the state of protons of the living human or non-human animal subject; and
(4) a step of diagnosing a glioblastoma in the subject, based on the T2-weighted image with respect to the state of protons;
wherein the T2 relaxation time in the presence of the MRI contrast agent has a value of 1.2 times or more of the value of the T2 relaxation time in the absence of the MRI contrast agent.

2. The method as recited in claim 1 , wherein the step of diagnosing glioblastoma in the subject comprises the comparison of the T2-weighted image with a second T2-weighted image obtained in the absence of the MRI contrast agent.

3. The method according to claim 2 , wherein the agent further comprises one or two or more metal-containing compounds.

4. The method according to claim 3 , wherein the metal-containing compound is an iron-containing compound.

Assignees

• Univ Kumamoto Nat Univ Corp
• Univ Of Occupational And Environmental Health Japan
• Sbi Pharmaceuticals Co Ltd
• Univ Of Occupational And Enviromental Health Japan

Inventors

• Yoneda Tetsuya
• Nishizawa Shigeru
• Yamamoto Junkoh
• Tanaka Tohru
• Itoh Hidenori

Classifications

• C07C229/22

  the carbon skeleton being further substituted by oxygen atoms · CPC title

• A61K49/10

  Organic compounds · CPC title

• A61B5/055 Primary

  involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging · CPC title

• G01R33/5601

  involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent · CPC title

• A61K49/1836

  the small organic molecule being a carboxylic acid having less than 8 carbon atoms in the main chain · CPC title